hip fractures in men with prostate cancer treated with
... pathological fractures. Skeletal metastases are more common in the vertebrae and pelvis than in the hip, so that if our estimates were heavily influenced by pathological fractures, we would have expected larger relative risks for these bones, which we did not observe. The methods of diagnosing and t ...
... pathological fractures. Skeletal metastases are more common in the vertebrae and pelvis than in the hip, so that if our estimates were heavily influenced by pathological fractures, we would have expected larger relative risks for these bones, which we did not observe. The methods of diagnosing and t ...
Update on the faster cancer treatment project November
... Faster cancer treatment project The faster cancer treatment project takes a patient pathway approach that covers surgical and non-surgical cancer treatment. The Government allocated $33 million over four years in Budget 2012 for the Ministry of Health (the Ministry) to implement the faster cancer tr ...
... Faster cancer treatment project The faster cancer treatment project takes a patient pathway approach that covers surgical and non-surgical cancer treatment. The Government allocated $33 million over four years in Budget 2012 for the Ministry of Health (the Ministry) to implement the faster cancer tr ...
Focal Treatments for Prostate Cancer
... and End Results data show age-adjusted cancer-specific mortality rates for men with prostate cancer have declined from 40 per 100,000 in 1992 to 22 per 100,000 in 2010. This decline has been attributed to a combination of earlier detection via prostate specific antigen (PSA) screening and improved t ...
... and End Results data show age-adjusted cancer-specific mortality rates for men with prostate cancer have declined from 40 per 100,000 in 1992 to 22 per 100,000 in 2010. This decline has been attributed to a combination of earlier detection via prostate specific antigen (PSA) screening and improved t ...
The Mechanism of Androgen Deprivation and the Androgen Receptor
... derives from testosterone (T). Most prostate tumors regress after therapy to prevent testosterone production by the testes, but the tumors eventually recur and cause death. The AR, a member of the steroid receptor family that is activated by testicular androgens, is the major regulatory transcriptio ...
... derives from testosterone (T). Most prostate tumors regress after therapy to prevent testosterone production by the testes, but the tumors eventually recur and cause death. The AR, a member of the steroid receptor family that is activated by testicular androgens, is the major regulatory transcriptio ...
Gene Expression and Biological Pathways in Tissue of Men with
... trial of fish oil and lycopene supplements with each compared to a placebo. The interventions consisted of two 15 mg lycopene softgel capsules daily (Lyc-O-MatoH donated by, Lycored, Israel) or three 1 gm fish oil capsules daily (that included 1098 mg eicosapentaenoic (EPA) and 549 mg docosahexaenoi ...
... trial of fish oil and lycopene supplements with each compared to a placebo. The interventions consisted of two 15 mg lycopene softgel capsules daily (Lyc-O-MatoH donated by, Lycored, Israel) or three 1 gm fish oil capsules daily (that included 1098 mg eicosapentaenoic (EPA) and 549 mg docosahexaenoi ...
Genomic Profiling Defines Subtypes of Prostate Cancer with the
... intertumoral heterogeneity, as well as updated information on disseminated and circulating tumor cells. The integrated analysis of all types of genetic alterations that culminate in altering critical biologic pathways may serve as the impetus for developing new therapeutics, repurposing agents used ...
... intertumoral heterogeneity, as well as updated information on disseminated and circulating tumor cells. The integrated analysis of all types of genetic alterations that culminate in altering critical biologic pathways may serve as the impetus for developing new therapeutics, repurposing agents used ...
The potential role of follicle-stimulating hormone in the
... patients with pre-existing CVD seemed to be at risk for the development of cardiovascular events with ADT. Accordingly, data from O’Farrell et al. [51] found that men undergoing ADT, who have pre-existing risk factors for CVD are at greater risk for adverse cardiovascular outcomes compared with thos ...
... patients with pre-existing CVD seemed to be at risk for the development of cardiovascular events with ADT. Accordingly, data from O’Farrell et al. [51] found that men undergoing ADT, who have pre-existing risk factors for CVD are at greater risk for adverse cardiovascular outcomes compared with thos ...
Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12
... Methods: Matched case-control study nested within the U.K. population–based Prostate testing for cancer and Treatment (ProtecT) study of prostate-specific antigen–detected prostate cancer in men ages 50 to 69 years. Plasma concentrations of folate, B12 (cobalamin), holo-haptocorrin, holo-transcobala ...
... Methods: Matched case-control study nested within the U.K. population–based Prostate testing for cancer and Treatment (ProtecT) study of prostate-specific antigen–detected prostate cancer in men ages 50 to 69 years. Plasma concentrations of folate, B12 (cobalamin), holo-haptocorrin, holo-transcobala ...
Pitch Letter - Pancreatic Cancer Canada
... and medical experts will come together to raise awareness about one of the deadliest forms of cancer, pancreatic cancer. Awareness is the first step in the efforts to demand more research and develop better resources to fight the disease. XXXXX XXXX will be available for in-studio or satellite inter ...
... and medical experts will come together to raise awareness about one of the deadliest forms of cancer, pancreatic cancer. Awareness is the first step in the efforts to demand more research and develop better resources to fight the disease. XXXXX XXXX will be available for in-studio or satellite inter ...
Pediatric Oncology: The Psychological Impact on the Family Unit
... Community Resources, Camps Hospice ...
... Community Resources, Camps Hospice ...
A Need for Basic Research on Fluid-Based Early
... or life threatening (20), whereas others progress rapidly. Methods to distinguish indolent and aggressive cancers are research topics, but few clinical tests are currently available. Mammaprint and OncoTypeDX gene expression signatures are prototype tests that are applied to breast tumor tissue to i ...
... or life threatening (20), whereas others progress rapidly. Methods to distinguish indolent and aggressive cancers are research topics, but few clinical tests are currently available. Mammaprint and OncoTypeDX gene expression signatures are prototype tests that are applied to breast tumor tissue to i ...
Targeting molecular resistance in castration
... progression to CRPC as well as resistance to abiraterone. Chang et al. [66] demonstrated that the 1245C mutation in HSD3B1, which was identified in treatment-naïve CRPC, was also identified in abiraterone-resistant xenograft models. Mostaghel et al. [67] demonstrated that abiraterone-treated LuCaP c ...
... progression to CRPC as well as resistance to abiraterone. Chang et al. [66] demonstrated that the 1245C mutation in HSD3B1, which was identified in treatment-naïve CRPC, was also identified in abiraterone-resistant xenograft models. Mostaghel et al. [67] demonstrated that abiraterone-treated LuCaP c ...
Lung Cancer Breast Cancer Bowel Cancer Cervical Cancer Ovarian
... approximately 5,000 are lesbian or bisexual. Cancer affects women of all ages. This leaflet gives an introduction to some of the common ones that affect women. There are many types of cancer, some are linked with smoking, alcohol use, sexually transmitted diseases and whether or not you've had child ...
... approximately 5,000 are lesbian or bisexual. Cancer affects women of all ages. This leaflet gives an introduction to some of the common ones that affect women. There are many types of cancer, some are linked with smoking, alcohol use, sexually transmitted diseases and whether or not you've had child ...
PDF - Journal of Cancer
... of single nucleotide polymorphisms (SNP). Kesarwani et al. demonstrated single nucleotide polymorphisms in tumor necrosis factor alpha may influence CaP risk, stage and progression in the North Indian population28. Another genetic factor that has been studied among several populations is the glutath ...
... of single nucleotide polymorphisms (SNP). Kesarwani et al. demonstrated single nucleotide polymorphisms in tumor necrosis factor alpha may influence CaP risk, stage and progression in the North Indian population28. Another genetic factor that has been studied among several populations is the glutath ...
Bowel Cancer awareness month
... More than nine out of ten new cases (94%) are diagnosed in people over the age of 50. But bowel cancer can affect any age. More than 2,500 new cases are diagnosed each year in people under the age of 50. 1 in 14 men (7%) and 1 in 19 women (5%) will be diagnosed with bowel cancer during their lifetim ...
... More than nine out of ten new cases (94%) are diagnosed in people over the age of 50. But bowel cancer can affect any age. More than 2,500 new cases are diagnosed each year in people under the age of 50. 1 in 14 men (7%) and 1 in 19 women (5%) will be diagnosed with bowel cancer during their lifetim ...
Targeting the α Receptor for Platelet-Derived
... Previous studies from our group have shown that bonemetastatic human prostate cancer cells express high levels of PDGFRα (21). The exposure of these cells to the soluble fraction of human bone marrow induces phosphorylation of PDGFRα and its downstream activation of the PI3K/Akt survival pathway (23 ...
... Previous studies from our group have shown that bonemetastatic human prostate cancer cells express high levels of PDGFRα (21). The exposure of these cells to the soluble fraction of human bone marrow induces phosphorylation of PDGFRα and its downstream activation of the PI3K/Akt survival pathway (23 ...
Trelstar® Patient Brochure
... suspension) 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, and 22.5 mg every 24 weeks administration is prescribed for the palliative treatment of advanced prostate cancer. ...
... suspension) 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, and 22.5 mg every 24 weeks administration is prescribed for the palliative treatment of advanced prostate cancer. ...
